Tagrisso plus chemotherapy improved progression-free survival in EGFR-positive NSCLC patients compared to placebo plus chemotherapy, with median survival of 8.4 vs. 4.4 months. Central nervous system ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC ...

FOX CHASE (WPVI) -- HIPEC is an often overlooked form of chemotherapy, with a long track record. It's improving survival rates in some abdominal cancers, however, some patients and doctors may not ...

A new pancreatic cancer drug being tested by doctors in Phoenix is showing promise, potentially doubling survival rates for ...

MRI-guided personalisation of neoadjuvant chemotherapy duration was associated with favourable 3-year event-free survival outcomes of more than 92% in patients with stage II-III HER2-positive breast ...

Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...